Clinical Research

The association between vitamin intake and the progression of metabolic dysfunction⁃associated fatty liver disease

  • Renling YAO ,
  • Yixuan ZHU ,
  • Rui HUANG ,
  • Jie LI
Expand
  • Department of Infectious Diseases,Nanjing Drum Tower Hospital,Affiliated Hospital of Medical School,Nanjing University,Nanjing 210008,China

Received date: 2023-12-28

  Online published: 2024-04-08

Abstract

Objective There is a Few studies explored the association between vitamin intake and metabolic dysfunction?associated fatty liver disease (MAFLD), while the existing results were still contradictory. This study aimed to investigate the association between dietary vitamins and all?cause mortality as well as fibrosis risk in patients with MAFLD. Methods The data were extracted from the third National Health and Nutrition Examination Surveys 1988-1994. Dietary vitamins was assessed using a 24 h diet recall, including vitamin A, vitamin B6, vitamin B12, vitamin C, vitamin D, thiamin, riboflavin, folic acid and α?tocopherol. The non?alcoholic fatty liver disease fibrosis score (NFS) < -1.455 was considered as non?advanced fibrosis, while NFS ≥ -1.455 was considered as advanced fibrosis. Results A total of 3844 MAFLD participants were included in this study. The median time of follow?up was 310 months. 1739 participants (45.3%) were deceased during the follow?up. The intake of thiamin, riboflavin, α?tocopherol, VB6, and VB12 were significantly higher in patients with NFS?determined non?advanced fibrosis (P < 0.05). After adjusting, a significantly lower risk of fibrosis was found in patients with the highest quartile (> 11.5 mg/d) of α?tocopherol intake compared to the lowest intake group (P = 0.031). Compared to the lowest quartile group, the risk of mortality was reduced by 0.34 folds in the group consuming the highest quartile amount (> 130 mg/d) of VC (HRs: 0.66, 95% CI: 0.51 ~ 0.85, P = 0.001). Conclusions More α?tocopherol intake reduced fibrosis grade in MAFLD patients. VC intake may reduce all?cause mortality in patients with MAFLD.

Cite this article

Renling YAO , Yixuan ZHU , Rui HUANG , Jie LI . The association between vitamin intake and the progression of metabolic dysfunction⁃associated fatty liver disease[J]. The Journal of Practical Medicine, 2024 , 40(6) : 820 -826 . DOI: 10.3969/j.issn.1006-5725.2024.06.015

References

1 LIM G E H, TANG A, NG C H, et al. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD[J]. Clin Gastroenterol Hepatol, 2023, 21(3): 619-629. doi:10.1016/j.cgh.2021.11.038
2 LEE H, LEE Y H, KIM S U, et al. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study[J]. Clin Gastroenterol Hepatol, 2021,19(10): 2138-2147. doi:10.1016/j.cgh.2020.12.022
3 JUNG C Y, KOH H B, PARK K H, et al. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study[J]. Diabetes Metab, 2022, 48(4):101344. doi:10.1016/j.diabet.2022.101344
4 LIU Z, LIN C, SUO C, et al. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers[J]. Metabolism, 2022,127: 154955. doi:10.1016/j.metabol.2021.154955
5 ALMER G, OPRIESSNIG P, WOLINSKI H, et al. Deficiency of B vitamins leads to cholesterol-independent atherogenic transformation of the aorta[J]. Biomed Pharmacother, 2022,154: 113640. doi:10.1016/j.biopha.2022.113640
6 TU Y R, TU K H, LEE C C, et al. Supplementation with Folic Acid and Cardiovascular Outcomes in End-Stage Kidney Disease: A Multi-Institution Cohort Study[J]. Nutrients, 2022, 14(19). doi:10.3390/nu14194162
7 SUTHERLAND J P, ZHOU A, HYPP?NEN E. Vitamin D Deficiency Increases Mortality Risk in the UK Biobank : A Nonlinear Mendelian Randomization Study[J]. Ann Intern Med, 2022, 175(11): 1552-1559. doi:10.7326/m21-3324
8 GUAN Y, XU Y, SU H, et al. Effect of serum vitamin D on metabolic associated fatty liver disease: a large population-based study[J]. Scand J Gastroenterol, 2022, 57(7): 862-871. doi:10.1080/00365521.2022.2039284
9 LEE H K, SHIN S R, HAN A L. Metabolic dysfunction associated fatty liver disease (MAFLD) and serum vitamin D concentration in South Korea[J]. Asia Pac J Clin Nutr, 2022, 31(2): 201-207.
10 BOWERMAN C, BHAKTA N R, BRAZZALE D, et al. A Race-neutral Approach to the Interpretation of Lung Function Measurements[J]. Am J Respir Crit Care Med, 2023, 207(6): 768-774. doi:10.1164/rccm.202205-0963oc
11 GAFFNEY A W, MCCORMICK D, WOOLHANDLER S, et al. Prognostic implications of differences in forced vital capacity in black and white US adults: Findings from NHANES III with long-term mortality follow-up[J]. EClinicalMedicine, 2021, 39: 101073. doi:10.1016/j.eclinm.2021.101073
12 LIU Y, GENG T, WAN Z, et al. Associations of Serum Folate and Vitamin B12 Levels With Cardiovascular Disease Mortality Among Patients With Type 2 Diabetes[J]. JAMA Netw Open, 2022, 5(1): e2146124. doi:10.1001/jamanetworkopen.2021.46124
13 MCEVOY J W, DAYA N, RAHMAN F, et al. Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes[J]. JAMA, 2020. 323(4): 329-338. doi:10.1001/jama.2019.21402
14 SRIPONGPUN P, KIM W R, MANNALITHARA A, et al. The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care[J]. Hepatology, 2023, 77(1): 256-267. doi:10.1002/hep.32545
15 WAN Z, GUO J, PAN A, et al. Association of Serum 25-Hydroxyvitamin D Concentrations With All-Cause and Cause-Specific Mortality Among Individuals With Diabetes[J]. Diabetes Care, 2021, 44(2): 350-357. doi:10.2337/dc20-1485
16 WANG L, YI J, GUO J, et al. Weigh change across adulthood is related to the presence of NAFLD: results from NHANES III[J]. J Transl Med, 2023,21(1): 142. doi:10.1186/s12967-023-04007-8
17 ZEMBIC A, ECKEL N, STEFAN N, et al. An Empirically Derived Definition of Metabolically Healthy Obesity Based on Risk of Cardiovascular and Total Mortality[J]. JAMA Netw Open, 2021,4(5): e218505. doi:10.1001/jamanetworkopen.2021.8505
18 ESLAM M, NEWSOME P N, SARIN S K, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. doi:10.1016/j.jhep.2020.07.045
19 KIM D, KIM W R, KIM H J, et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States[J]. Hepatology, 2013, 57(4): 1357-1365. doi:10.1002/hep.26156
20 SILVA A C O, BONFIM M, FONTES J L M, et al. C57BL/6 Mice Pretreated With Alpha-Tocopherol Show a Better Outcome of Trypanosoma cruzi Infection With Less Tissue Inflammation and Fibrosis[J]. Front Immunol, 2022, 13: 833560. doi:10.3389/fimmu.2022.833560
21 DEMIREL-YALCINER T, SOZEN E, OZALTIN E, et al. alpha-Tocopherol supplementation reduces inflammation and apoptosis in high cholesterol mediated nonalcoholic steatohepatitis[J]. Biofactors, 2021, 47(3): 403-413. doi:10.1002/biof.1700
22 STEPANIAK U, MICEK A, GROSSO G, et al. Antioxidant vitamin intake and mortality in three Central and Eastern European urban populations: the HAPIEE study[J]. Eur J Nutr, 2016, 55(2): 547-560. doi:10.1007/s00394-015-0871-8
23 FORD E S, LI C, CUNNINGHAM T J, et al. Associations between antioxidants and all-cause mortality among US adults with obstructive lung function[J]. Br J Nutr, 2014, 112(10): 1662-1673. doi:10.1017/s0007114514002669
24 LIM S, KIM J W, TARGHER G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease[J]. Trends Endocrinol Metab, 2021, 32(7): 500-514. doi:10.1016/j.tem.2021.04.008
25 JANG I S, KO Y H, MOON Y S, et al. Effects of Vitamin C or E on the Pro-inflammatory Cytokines, Heat Shock Protein 70 and Antioxidant Status in Broiler Chicks under Summer Conditions[J]. Asian-Australas J Anim Sci, 2014, 27(5): 749-756. doi:10.5713/ajas.2013.13852
26 PELUSO I, VILLANO D V, ROBERTS S A, et al. Consumption of mixed fruit-juice drink and vitamin C reduces postprandial stress induced by a high fat meal in healthy overweight subjects[J]. Curr Pharm Des, 2014, 20(6): 1020-1024. doi:10.2174/138161282006140220144802
Outlines

/